{
    "text": "Ivermectin inhibits the replication of SARS-CoV-2 in vitro at concentrations not readily achievable with currently approved doses. There is limited evidence to support its clinical use in COVID-19 patients. We conducted a Pilot, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a single dose of ivermectin reduce the transmission of SARS-CoV-2 when administered early after disease onset.",
    "sourcedb": "PubMed",
    "sourceid": "33495752",
    "blocks": [
        {
            "id": "T1",
            "span": {
                "begin": 0,
                "end": 417
            },
            "obj": "What a tremendously great summary!"
        }
    ]
}